 Michael Strong
Concepts (291)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium Infections, Nontuberculous | 26 | 2024 | 353 | 6.030 |
Why?
| | Genome, Bacterial | 15 | 2024 | 134 | 4.090 |
Why?
| | Mycobacterium | 11 | 2023 | 106 | 3.740 |
Why?
| | Nontuberculous Mycobacteria | 16 | 2024 | 204 | 3.350 |
Why?
| | Mycobacterium tuberculosis | 19 | 2023 | 309 | 2.850 |
Why?
| | Mycobacterium abscessus | 11 | 2024 | 107 | 2.320 |
Why?
| | Whole Genome Sequencing | 4 | 2024 | 129 | 1.730 |
Why?
| | Mycobacterium Infections | 6 | 2021 | 62 | 1.630 |
Why?
| | Tuberculosis | 8 | 2023 | 273 | 1.350 |
Why?
| | Cystic Fibrosis | 12 | 2024 | 1066 | 1.310 |
Why?
| | Phylogeny | 14 | 2021 | 850 | 1.130 |
Why?
| | Genomics | 6 | 2021 | 718 | 1.110 |
Why?
| | Antitubercular Agents | 8 | 2023 | 200 | 0.990 |
Why?
| | Genotype | 5 | 2024 | 1833 | 0.980 |
Why?
| | Genome, Viral | 3 | 2021 | 128 | 0.970 |
Why?
| | Bacteriophages | 3 | 2022 | 86 | 0.930 |
Why?
| | Lung Diseases | 3 | 2022 | 741 | 0.900 |
Why?
| | Methylobacterium | 1 | 2023 | 3 | 0.870 |
Why?
| | Sequence Analysis, DNA | 8 | 2022 | 778 | 0.840 |
Why?
| | Protein Domains | 1 | 2024 | 256 | 0.810 |
Why?
| | Drug Resistance, Bacterial | 8 | 2024 | 175 | 0.790 |
Why?
| | Computational Biology | 7 | 2018 | 596 | 0.790 |
Why?
| | Genetic Variation | 7 | 2021 | 939 | 0.740 |
Why?
| | Viral Nonstructural Proteins | 1 | 2021 | 58 | 0.730 |
Why?
| | Databases, Genetic | 3 | 2018 | 230 | 0.700 |
Why?
| | Lysogeny | 1 | 2020 | 5 | 0.700 |
Why?
| | Prophages | 1 | 2020 | 7 | 0.700 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 109 | 0.690 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2020 | 646 | 0.680 |
Why?
| | Viruses | 1 | 2021 | 100 | 0.670 |
Why?
| | Bacterial Proteins | 10 | 2016 | 836 | 0.670 |
Why?
| | Plasmids | 1 | 2020 | 359 | 0.650 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1843 | 0.650 |
Why?
| | Hawaii | 5 | 2023 | 32 | 0.610 |
Why?
| | Mutation | 3 | 2021 | 3717 | 0.600 |
Why?
| | Soil Microbiology | 2 | 2020 | 210 | 0.580 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2021 | 2060 | 0.580 |
Why?
| | DNA-Binding Proteins | 3 | 2024 | 1445 | 0.580 |
Why?
| | DNA, Bacterial | 5 | 2021 | 321 | 0.570 |
Why?
| | Microbial Sensitivity Tests | 5 | 2024 | 348 | 0.570 |
Why?
| | Cardiac Surgical Procedures | 2 | 2019 | 506 | 0.510 |
Why?
| | Respiratory System | 1 | 2017 | 155 | 0.510 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 283 | 0.500 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2021 | 329 | 0.490 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2016 | 71 | 0.490 |
Why?
| | Software | 4 | 2022 | 608 | 0.470 |
Why?
| | Humans | 55 | 2024 | 129625 | 0.450 |
Why?
| | Cross Infection | 3 | 2021 | 217 | 0.440 |
Why?
| | Skin Diseases, Bacterial | 1 | 2013 | 21 | 0.430 |
Why?
| | Systems Biology | 1 | 2014 | 60 | 0.420 |
Why?
| | Microbiota | 1 | 2021 | 733 | 0.420 |
Why?
| | Disease Outbreaks | 3 | 2024 | 349 | 0.420 |
Why?
| | Tuberculosis, Pulmonary | 4 | 2016 | 135 | 0.410 |
Why?
| | Respiratory Tract Diseases | 1 | 2014 | 148 | 0.390 |
Why?
| | Molybdenum | 2 | 2021 | 9 | 0.360 |
Why?
| | Sputum | 6 | 2021 | 302 | 0.340 |
Why?
| | Metagenomics | 2 | 2021 | 156 | 0.330 |
Why?
| | Genetic Predisposition to Disease | 2 | 2016 | 2274 | 0.330 |
Why?
| | Lung | 6 | 2023 | 3938 | 0.310 |
Why?
| | RNA, Viral | 2 | 2024 | 620 | 0.300 |
Why?
| | Protein Binding | 3 | 2024 | 2124 | 0.300 |
Why?
| | RNA | 1 | 2014 | 882 | 0.280 |
Why?
| | Genes, Bacterial | 4 | 2017 | 157 | 0.270 |
Why?
| | United States | 9 | 2022 | 13871 | 0.250 |
Why?
| | Chromosome Mapping | 2 | 2023 | 505 | 0.250 |
Why?
| | Bacterial Typing Techniques | 2 | 2017 | 43 | 0.250 |
Why?
| | Proteins | 2 | 2013 | 944 | 0.240 |
Why?
| | Cluster Analysis | 4 | 2014 | 482 | 0.240 |
Why?
| | Tuberculosis, Multidrug-Resistant | 3 | 2016 | 57 | 0.230 |
Why?
| | Proteomics | 3 | 2006 | 1055 | 0.230 |
Why?
| | Evolution, Molecular | 2 | 2021 | 466 | 0.230 |
Why?
| | Virulence | 3 | 2020 | 255 | 0.220 |
Why?
| | Soil | 3 | 2022 | 225 | 0.220 |
Why?
| | Reference Standards | 1 | 2024 | 176 | 0.220 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2024 | 98 | 0.210 |
Why?
| | Data Accuracy | 1 | 2023 | 58 | 0.210 |
Why?
| | Multigene Family | 1 | 2003 | 199 | 0.210 |
Why?
| | Immunity, Innate | 2 | 2021 | 805 | 0.200 |
Why?
| | Gene Expression Regulation, Bacterial | 5 | 2023 | 323 | 0.200 |
Why?
| | Phosphoproteins | 1 | 2024 | 335 | 0.190 |
Why?
| | Protein Conformation, beta-Strand | 1 | 2021 | 15 | 0.190 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2021 | 15 | 0.190 |
Why?
| | Furin | 1 | 2021 | 14 | 0.190 |
Why?
| | Asia | 1 | 2021 | 58 | 0.190 |
Why?
| | Africa | 1 | 2021 | 99 | 0.190 |
Why?
| | Epidemiological Monitoring | 1 | 2021 | 50 | 0.180 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 109 | 0.180 |
Why?
| | Gene Expression Profiling | 7 | 2023 | 1687 | 0.180 |
Why?
| | Adenosine Monophosphate | 1 | 2021 | 63 | 0.180 |
Why?
| | Genome Size | 1 | 2020 | 11 | 0.180 |
Why?
| | Alanine | 1 | 2021 | 142 | 0.180 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 139 | 0.180 |
Why?
| | Europe | 1 | 2021 | 363 | 0.180 |
Why?
| | Models, Molecular | 3 | 2016 | 1491 | 0.180 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2022 | 487 | 0.180 |
Why?
| | Structure-Activity Relationship | 2 | 2016 | 545 | 0.170 |
Why?
| | Amino Acid Substitution | 1 | 2021 | 283 | 0.170 |
Why?
| | Bacteriological Techniques | 1 | 2021 | 69 | 0.170 |
Why?
| | Water Pollution | 1 | 2020 | 7 | 0.170 |
Why?
| | Killer Cells, Natural | 2 | 2014 | 426 | 0.170 |
Why?
| | Metagenome | 1 | 2021 | 140 | 0.170 |
Why?
| | Water Quality | 1 | 2020 | 29 | 0.170 |
Why?
| | Antigens, Bacterial | 2 | 2014 | 119 | 0.170 |
Why?
| | Adaptation, Physiological | 3 | 2023 | 514 | 0.160 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2020 | 77 | 0.160 |
Why?
| | Immune Evasion | 1 | 2020 | 56 | 0.160 |
Why?
| | Membrane Lipids | 1 | 2020 | 91 | 0.160 |
Why?
| | Pneumonia | 2 | 2023 | 617 | 0.160 |
Why?
| | Protein Conformation | 2 | 2016 | 863 | 0.150 |
Why?
| | Databases, Factual | 2 | 2021 | 1269 | 0.150 |
Why?
| | Phospholipids | 1 | 2020 | 216 | 0.150 |
Why?
| | Binding Sites | 1 | 2021 | 1248 | 0.150 |
Why?
| | Fomites | 1 | 2017 | 6 | 0.140 |
Why?
| | Mycolic Acids | 1 | 2017 | 7 | 0.140 |
Why?
| | Base Composition | 1 | 2017 | 76 | 0.140 |
Why?
| | Oregon | 1 | 2017 | 70 | 0.140 |
Why?
| | Virus Diseases | 1 | 2020 | 210 | 0.140 |
Why?
| | Biological Specimen Banks | 1 | 2018 | 97 | 0.140 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 1705 | 0.140 |
Why?
| | Water Supply | 1 | 2017 | 74 | 0.140 |
Why?
| | Transcriptome | 3 | 2023 | 876 | 0.130 |
Why?
| | Surgical Equipment | 1 | 2016 | 13 | 0.130 |
Why?
| | Brazil | 2 | 2014 | 154 | 0.130 |
Why?
| | Gene Expression | 1 | 2021 | 1465 | 0.130 |
Why?
| | DNA Gyrase | 1 | 2016 | 12 | 0.130 |
Why?
| | Equipment Contamination | 1 | 2016 | 56 | 0.130 |
Why?
| | Fluoroquinolones | 1 | 2016 | 45 | 0.130 |
Why?
| | Web Browser | 1 | 2015 | 12 | 0.130 |
Why?
| | DNA Barcoding, Taxonomic | 1 | 2015 | 18 | 0.130 |
Why?
| | Catalase | 1 | 2016 | 128 | 0.120 |
Why?
| | Gene Ontology | 1 | 2015 | 49 | 0.120 |
Why?
| | Antiviral Agents | 1 | 2021 | 715 | 0.120 |
Why?
| | Molecular Sequence Annotation | 1 | 2015 | 88 | 0.120 |
Why?
| | Isoniazid | 1 | 2016 | 63 | 0.120 |
Why?
| | Rifampin | 1 | 2016 | 83 | 0.120 |
Why?
| | Housing | 1 | 2016 | 130 | 0.120 |
Why?
| | Bacterial Toxins | 1 | 2016 | 104 | 0.120 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 524 | 0.120 |
Why?
| | DNA Mutational Analysis | 1 | 2016 | 382 | 0.120 |
Why?
| | Data Mining | 1 | 2016 | 110 | 0.120 |
Why?
| | Viral Core Proteins | 1 | 2014 | 21 | 0.110 |
Why?
| | Adaptive Immunity | 1 | 2016 | 161 | 0.110 |
Why?
| | Colorado | 5 | 2024 | 4404 | 0.110 |
Why?
| | Tuberculosis Vaccines | 1 | 2014 | 4 | 0.110 |
Why?
| | Genetic Linkage | 2 | 2006 | 298 | 0.110 |
Why?
| | Biofilms | 1 | 2016 | 244 | 0.110 |
Why?
| | DNA Repeat Expansion | 1 | 2013 | 7 | 0.110 |
Why?
| | Operon | 2 | 2003 | 64 | 0.110 |
Why?
| | Transcription, Genetic | 5 | 2023 | 1418 | 0.100 |
Why?
| | Conserved Sequence | 2 | 2003 | 227 | 0.100 |
Why?
| | Galectins | 1 | 2013 | 22 | 0.100 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2020 | 634 | 0.100 |
Why?
| | Phenotype | 3 | 2016 | 3075 | 0.100 |
Why?
| | Hepacivirus | 1 | 2014 | 239 | 0.100 |
Why?
| | Virulence Factors | 1 | 2014 | 157 | 0.100 |
Why?
| | Adult | 10 | 2024 | 35599 | 0.100 |
Why?
| | Epidemics | 1 | 2013 | 82 | 0.100 |
Why?
| | Biomedical Research | 1 | 2018 | 640 | 0.100 |
Why?
| | Herpesvirus 4, Human | 1 | 2012 | 156 | 0.090 |
Why?
| | Neurodegenerative Diseases | 1 | 2013 | 113 | 0.090 |
Why?
| | Herpesviridae Infections | 1 | 2013 | 141 | 0.090 |
Why?
| | DNA, Viral | 1 | 2012 | 347 | 0.090 |
Why?
| | Base Sequence | 1 | 2013 | 2147 | 0.080 |
Why?
| | Time Factors | 2 | 2021 | 6555 | 0.080 |
Why?
| | Species Specificity | 2 | 2020 | 574 | 0.080 |
Why?
| | Aged | 6 | 2021 | 22061 | 0.070 |
Why?
| | Middle Aged | 7 | 2021 | 31136 | 0.070 |
Why?
| | Bayes Theorem | 2 | 2021 | 375 | 0.070 |
Why?
| | Signal Transduction | 2 | 2016 | 4931 | 0.070 |
Why?
| | Public Health | 1 | 2012 | 487 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2021 | 3378 | 0.070 |
Why?
| | Cell Wall | 2 | 2006 | 55 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2542 | 0.060 |
Why?
| | Treatment Failure | 2 | 2021 | 339 | 0.060 |
Why?
| | Female | 9 | 2024 | 68734 | 0.060 |
Why?
| | Uganda | 2 | 2016 | 70 | 0.060 |
Why?
| | Solubility | 1 | 2006 | 232 | 0.060 |
Why?
| | Aged, 80 and over | 4 | 2021 | 7052 | 0.060 |
Why?
| | Disease Models, Animal | 3 | 2023 | 4078 | 0.060 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 5075 | 0.060 |
Why?
| | Cloning, Molecular | 1 | 2006 | 525 | 0.060 |
Why?
| | Crystallography, X-Ray | 1 | 2006 | 438 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2016 | 10219 | 0.060 |
Why?
| | Biomarkers | 1 | 2015 | 3968 | 0.060 |
Why?
| | Protein Kinases | 2 | 2016 | 318 | 0.060 |
Why?
| | Arizona | 1 | 2024 | 78 | 0.060 |
Why?
| | Iron | 2 | 2022 | 282 | 0.050 |
Why?
| | Galactans | 1 | 2003 | 4 | 0.050 |
Why?
| | Glutamate-Ammonia Ligase | 1 | 2003 | 7 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 756 | 0.050 |
Why?
| | Mexico | 1 | 2024 | 191 | 0.050 |
Why?
| | Genome | 1 | 2006 | 278 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2018 | 3080 | 0.050 |
Why?
| | Dust | 1 | 2023 | 94 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2014 | 220 | 0.050 |
Why?
| | Male | 7 | 2022 | 63670 | 0.050 |
Why?
| | Stem Cell Transplantation | 1 | 2024 | 164 | 0.050 |
Why?
| | Proteome | 2 | 2006 | 438 | 0.050 |
Why?
| | Mycobacterium avium Complex | 1 | 2023 | 88 | 0.050 |
Why?
| | Oxides | 1 | 2022 | 41 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2006 | 745 | 0.050 |
Why?
| | HIV Infections | 1 | 2016 | 2730 | 0.050 |
Why?
| | Clarithromycin | 1 | 2021 | 28 | 0.050 |
Why?
| | Armadillos | 1 | 2021 | 2 | 0.050 |
Why?
| | Mycobacterium leprae | 1 | 2021 | 8 | 0.040 |
Why?
| | Macrolides | 1 | 2021 | 60 | 0.040 |
Why?
| | Clone Cells | 1 | 2021 | 262 | 0.040 |
Why?
| | Cell Membrane | 2 | 2020 | 734 | 0.040 |
Why?
| | Bioreactors | 1 | 2021 | 42 | 0.040 |
Why?
| | Smokers | 1 | 2021 | 138 | 0.040 |
Why?
| | Benchmarking | 1 | 2022 | 176 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2023 | 1042 | 0.040 |
Why?
| | Macrophages | 2 | 2020 | 1488 | 0.040 |
Why?
| | Microbial Viability | 1 | 2021 | 83 | 0.040 |
Why?
| | Water | 1 | 2023 | 441 | 0.040 |
Why?
| | Chromatography, Thin Layer | 1 | 2020 | 23 | 0.040 |
Why?
| | Cathelicidins | 1 | 2020 | 37 | 0.040 |
Why?
| | THP-1 Cells | 1 | 2020 | 22 | 0.040 |
Why?
| | Glycolipids | 1 | 2020 | 42 | 0.040 |
Why?
| | Genetics, Population | 1 | 2021 | 200 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 682 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 328 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2023 | 5455 | 0.040 |
Why?
| | Mice | 3 | 2023 | 16961 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2016 | 2708 | 0.040 |
Why?
| | Hospitals | 1 | 2021 | 637 | 0.030 |
Why?
| | Gambia | 1 | 2016 | 14 | 0.030 |
Why?
| | Macrophages, Alveolar | 1 | 2020 | 389 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2023 | 898 | 0.030 |
Why?
| | Regulon | 1 | 2016 | 35 | 0.030 |
Why?
| | Animals | 4 | 2023 | 35391 | 0.030 |
Why?
| | Nitrogen Oxides | 1 | 2016 | 52 | 0.030 |
Why?
| | Granuloma | 1 | 2016 | 89 | 0.030 |
Why?
| | India | 1 | 2016 | 171 | 0.030 |
Why?
| | Escherichia coli | 1 | 2020 | 767 | 0.030 |
Why?
| | Risk Factors | 2 | 2021 | 9786 | 0.030 |
Why?
| | Body Temperature Regulation | 1 | 2016 | 96 | 0.030 |
Why?
| | Prevalence | 1 | 2022 | 2564 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2016 | 182 | 0.030 |
Why?
| | Specimen Handling | 1 | 2016 | 162 | 0.030 |
Why?
| | Young Adult | 3 | 2016 | 12455 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2016 | 215 | 0.030 |
Why?
| | Latent Tuberculosis | 1 | 2015 | 67 | 0.030 |
Why?
| | Adolescent | 3 | 2021 | 20412 | 0.030 |
Why?
| | CD56 Antigen | 1 | 2014 | 36 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2016 | 318 | 0.030 |
Why?
| | Multilocus Sequence Typing | 1 | 2014 | 13 | 0.030 |
Why?
| | Lymphocyte Subsets | 1 | 2014 | 84 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 503 | 0.030 |
Why?
| | Extracellular Space | 1 | 2014 | 120 | 0.030 |
Why?
| | Guinea Pigs | 1 | 2014 | 157 | 0.030 |
Why?
| | C9orf72 Protein | 1 | 2013 | 9 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1499 | 0.030 |
Why?
| | Cell Count | 1 | 2014 | 312 | 0.030 |
Why?
| | Autopsy | 1 | 2013 | 90 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2017 | 463 | 0.030 |
Why?
| | United Kingdom | 1 | 2014 | 257 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 126 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1035 | 0.030 |
Why?
| | Muromegalovirus | 1 | 2013 | 21 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1213 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2014 | 311 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2013 | 30 | 0.030 |
Why?
| | tau Proteins | 1 | 2013 | 76 | 0.030 |
Why?
| | Receptors, Virus | 1 | 2013 | 83 | 0.030 |
Why?
| | Interleukin-15 | 1 | 2013 | 83 | 0.020 |
Why?
| | Interleukin-12 | 1 | 2013 | 118 | 0.020 |
Why?
| | Gene Deletion | 1 | 2014 | 382 | 0.020 |
Why?
| | Microtubule-Associated Proteins | 1 | 2013 | 192 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2014 | 281 | 0.020 |
Why?
| | Prospective Studies | 1 | 2023 | 7135 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2013 | 374 | 0.020 |
Why?
| | Hepatitis C | 1 | 2014 | 243 | 0.020 |
Why?
| | Drug Discovery | 1 | 2012 | 130 | 0.020 |
Why?
| | Genetic Testing | 1 | 2013 | 430 | 0.020 |
Why?
| | Viral Proteins | 1 | 2012 | 327 | 0.020 |
Why?
| | Child | 2 | 2021 | 20884 | 0.020 |
Why?
| | Hypoxia | 1 | 2016 | 1084 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2012 | 2835 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2013 | 1125 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2013 | 2881 | 0.020 |
Why?
| | Vaccination | 1 | 2014 | 1347 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2013 | 4084 | 0.010 |
Why?
| | Biological Transport | 1 | 2006 | 404 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2013 | 4894 | 0.010 |
Why?
| | DNA Repair | 1 | 2006 | 210 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2021 | 14522 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 5426 | 0.010 |
Why?
| | Up-Regulation | 1 | 2006 | 840 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 2006 | 503 | 0.010 |
Why?
| | Amino Acids | 1 | 2006 | 487 | 0.010 |
Why?
|
|
Strong's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|